348 related articles for article (PubMed ID: 34523422)
1. Reviewing pharmacogenetics to advance precision medicine for opioids.
Magarbeh L; Gorbovskaya I; Le Foll B; Jhirad R; Müller DJ
Biomed Pharmacother; 2021 Oct; 142():112060. PubMed ID: 34523422
[TBL] [Abstract][Full Text] [Related]
2. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
Ruano G; Kost JA
Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
5. Review of Opioid Pharmacogenetics and Considerations for Pain Management.
Owusu Obeng A; Hamadeh I; Smith M
Pharmacotherapy; 2017 Sep; 37(9):1105-1121. PubMed ID: 28699646
[TBL] [Abstract][Full Text] [Related]
6. Use of pharmacogenetic data to guide individualized opioid prescribing after surgery.
Rocco R; Thiels CA; Ubl DS; Moyer AM; Habermann EB; Cassivi SD
Surgery; 2019 Oct; 166(4):476-482. PubMed ID: 31320226
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
Smith DM; Weitzel KW; Elsey AR; Langaee T; Gong Y; Wake DT; Duong BQ; Hagen M; Harle CA; Mercado E; Nagoshi Y; Newsom K; Wright A; Rosenberg EI; Starostik P; Clare-Salzler MJ; Schmidt SO; Fillingim RB; Johnson JA; Cavallari LH
Genet Med; 2019 Aug; 21(8):1842-1850. PubMed ID: 30670877
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S
Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of Postoperative Pain Management: A Review.
Aroke EN; Kittelsrud JM
AANA J; 2020 Jun; 88(3):229-236. PubMed ID: 32442101
[TBL] [Abstract][Full Text] [Related]
11. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
[TBL] [Abstract][Full Text] [Related]
12. Pain polymorphisms and opioids: An evidence based review.
Vieira CMP; Fragoso RM; Pereira D; Medeiros R
Mol Med Rep; 2019 Mar; 19(3):1423-1434. PubMed ID: 30592275
[TBL] [Abstract][Full Text] [Related]
13. Clinical prediction of opioid use disorder in chronic pain patients: a cohort-retrospective study with a pharmacogenetic approach.
Escorial M; Muriel J; Agulló L; Zandonai T; Margarit C; Morales D; Peiró AM
Minerva Anestesiol; 2024 May; 90(5):386-396. PubMed ID: 38619184
[TBL] [Abstract][Full Text] [Related]
14. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.
Lötsch J; Skarke C; Liefhold J; Geisslinger G
Clin Pharmacokinet; 2004; 43(14):983-1013. PubMed ID: 15530129
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.
Ballester P; Muriel J; Peiró AM
Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):261-275. PubMed ID: 35649041
[TBL] [Abstract][Full Text] [Related]
16. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of Postoperative Nausea and Vomiting.
Aroke EN; Hicks TL
J Perianesth Nurs; 2019 Dec; 34(6):1088-1105. PubMed ID: 31227296
[TBL] [Abstract][Full Text] [Related]
18. The Role of Pharmacogenomics in Opioid Prescribing.
Wong AK; Somogyi AA; Rubio J; Philip J
Curr Treat Options Oncol; 2022 Oct; 23(10):1353-1369. PubMed ID: 36001223
[TBL] [Abstract][Full Text] [Related]
19. Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics.
Solhaug V; Molden E
Scand J Pain; 2017 Oct; 17():193-200. PubMed ID: 29054049
[TBL] [Abstract][Full Text] [Related]
20. Clinical application of pharmacogenetics in pain management.
Smith DM; Weitzel KW; Cavallari LH; Elsey AR; Schmidt SO
Per Med; 2018 Mar; 15(2):117-126. PubMed ID: 29714124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
